Anastrozole Tablet
Product Images NDC 16729-035

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 16729-035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle (Anastrozole 1mg 30 Label)

Anastrozole Tablets, USP 1 mg oral tablets packaging label from Accord Healthcare Inc. The label includes NDC 16729-035-10 and indicates a package count of 30 tablets. It contains storage instructions, a warning to keep out of reach of children, and directions for the pharmacist to dispense with patient information leaflet. Manufactured by Intas Pharmaceuticals Limited, India.*

FDA Label Image

Figure 1 (Anastrozole Fig1)

A survival curve chart comparing disease-free survival over 90 months for patients treated with anastrozole versus tamoxifen. The vertical axis shows the proportion alive and disease-free, and the horizontal axis represents time in months. A legend identifies the lines for anastrozole (dashed) and tamoxifen (solid). A table below lists the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 2 (Anastrozole Fig2)

A Kaplan-Meier survival curve chart showing disease-free survival in months for patients randomized to anastrozole or tamoxifen treatments. The y-axis represents the proportion alive and disease-free, ranging from 0 to 1.0, while the x-axis shows months up to 96. The graph includes a legend distinguishing the two treatments with different line styles and a table of patient numbers at risk below the x-axis for each treatment group at various time points.*

FDA Label Image

Figure 3 (Anastrozole Fig3)

A Kaplan-Meier curve chart comparing the progression-free proportion over time (in months) between Anastrozole and Tamoxifen treatments. The chart displays the patient risk numbers at various time points up to 120 months, with the vertical axis showing progression-free proportion and the horizontal axis showing time to event in months. A note indicates patient follow-up of 120 months was 29.4%.*

FDA Label Image

Figure 4 (Anastrozole Fig4)

A Kaplan-Meier survival curve chart comparing randomized treatments of Anastrozole and Tamoxifen, showing the proportion of patients event-free over time up to 120 months. The horizontal axis represents time to event in months, and the vertical axis represents the proportion event-free. The chart includes the number of patients at risk at various time points below the axis.*

FDA Label Image

Figure 5 (Anastrozole Fig5)

A line chart displaying the proportion of patients not experiencing progression over time (in months) for two randomized treatments: Anastrozole and Tamoxifen. The x-axis shows time to progression in months, and the y-axis represents the proportion not progressing. The chart compares the progression-free survival between the two treatments.*

FDA Label Image

Figure 6 (Anastrozole Fig6)

A Kaplan-Meier curve graph comparing progression-free survival over time (months) between two randomized treatments: Anastrozole and Tamoxifen. The Y-axis shows the proportion not progressed, and the X-axis shows time to progression in months, with patient risk numbers listed below.*

FDA Label Image

Chemical Structure For Anastrozole (Anastrozole Str)

Chemical structure of anastrozole, depicted as a molecular diagram showing the arrangement of atoms and chemical bonds for this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.